GlaxoSmithKline (GSK) Facing More Corruption Claims

GlaxoSmithKline (GSK) is facing another round of corruption claims, but these ones don’t come from China.

glaxosmithkline-gsk-corruptionThe new allegations of corruption against GlaxoSmithKline come from Syria. A whistleblower email sent to Reuters claims that the company used bribes in the country to get business. These claims date as far back as 2010 and refer to consumer healthcare operations in Syria that shutdown in 2012.

The email received by Reuters GlaxoSmithKline claims that the company’s internal control failed to stop corruption in the country. GSK said it has a zero-tolerance policy for corruption and that it will look into the allegation against it.

GlaxoSmithKline’s troubles with corruption in China haven’t deterred the company and it said it remains dedicated to the area.

GSK shares were down 3% as of Friday afternoon.

Hot Stocks to Watch

Article printed from InvestorPlace Media,

©2023 InvestorPlace Media, LLC